About Amphastar Pharmaceuticals, Inc.
https://www.amphastar.comAmphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.
CEO
Yongfeng Zhang
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 179
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Needham
Buy
Wells Fargo
Overweight
B of A Securities
Neutral
Piper Sandler
Neutral
JP Morgan
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:5.94M
Value:$164.96M
BLACKROCK, INC.
Shares:5.49M
Value:$152.27M
BLACKROCK FUND ADVISORS
Shares:3.9M
Value:$108.27M
Summary
Showing Top 3 of 293
About Amphastar Pharmaceuticals, Inc.
https://www.amphastar.comAmphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $191.84M ▲ | $73.33M ▲ | $17.35M ▼ | 9.04% ▼ | $0.38 ▼ | $41.93M ▼ |
| Q2-2025 | $174.41M ▲ | $44.31M ▼ | $31.03M ▲ | 17.79% ▲ | $0.66 ▲ | $61.85M ▲ |
| Q1-2025 | $170.53M ▼ | $47.96M ▲ | $25.29M ▼ | 14.83% ▼ | $0.53 ▼ | $52.35M ▼ |
| Q4-2024 | $186.52M ▼ | $41.5M ▼ | $37.96M ▼ | 20.35% ▼ | $0.78 ▼ | $65.05M ▼ |
| Q3-2024 | $188.82M | $44.89M | $40.43M | 21.41% | $0.83 | $68.81M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $278.64M ▲ | $1.67B ▲ | $889.48M ▲ | $776.75M ▲ |
| Q2-2025 | $231.75M ▼ | $1.62B ▼ | $857.85M ▼ | $757.48M ▲ |
| Q1-2025 | $236.88M ▲ | $1.63B ▲ | $874.99M ▲ | $751.28M ▲ |
| Q4-2024 | $221.65M ▼ | $1.58B ▲ | $845.17M ▲ | $732.3M ▲ |
| Q3-2024 | $250.49M | $1.55B | $817.5M | $727.68M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $17.35M ▼ | $52.58M ▲ | $-19.62M ▼ | $-4.35M ▲ | $28.58M ▲ | $47.23M ▲ |
| Q2-2025 | $31.03M ▲ | $35.59M ▲ | $-625K ▼ | $-30.2M ▼ | $4.91M ▼ | $25.03M ▲ |
| Q1-2025 | $25.29M ▼ | $35.08M ▲ | $10.48M ▲ | $-14.5M ▲ | $31.17M ▲ | $24.38M ▲ |
| Q4-2024 | $37.96M ▼ | $29.02M ▼ | $-35.68M ▼ | $-33.84M ▼ | $-40.51M ▼ | $16.61M ▼ |
| Q3-2024 | $40.43M | $59.96M | $-34.59M | $-22.82M | $2.5M | $46.17M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 BAQSIMI | $0 ▲ | $0 ▲ | $50.00M ▲ | $50.00M ▲ |
 Epinephrine | $0 ▲ | $0 ▲ | $20.00M ▲ | $20.00M ▲ |
 Glucagon | $0 ▲ | $0 ▲ | $20.00M ▲ | $10.00M ▼ |
 Lidocaine | $0 ▲ | $0 ▲ | $10.00M ▲ | $10.00M ▲ |
 Other Products | $0 ▲ | $0 ▲ | $50.00M ▲ | $60.00M ▲ |
 Primatene MIST | $0 ▲ | $0 ▲ | $20.00M ▲ | $30.00M ▲ |
 Research and development services | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Total product revenues net | $0 ▲ | $0 ▲ | $170.00M ▲ | $190.00M ▲ |
 Product | $520.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 CHINA | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 FRANCE | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 UNITED STATES | $180.00M ▲ | $180.00M ▲ | $170.00M ▼ | $160.00M ▼ |
CEO
Yongfeng Zhang
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 179
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Needham
Buy
Wells Fargo
Overweight
B of A Securities
Neutral
Piper Sandler
Neutral
JP Morgan
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:5.94M
Value:$164.96M
BLACKROCK, INC.
Shares:5.49M
Value:$152.27M
BLACKROCK FUND ADVISORS
Shares:3.9M
Value:$108.27M
Summary
Showing Top 3 of 293